Venous thromboembolism risk with contemporary lenalidomide‐based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta‐analysis
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Venous thromboembolism risk with contemporary lenalidomide‐based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta‐analysis
Authors
Keywords
-
Journal
CANCER
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-01-08
DOI
10.1002/cncr.32682
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Derivation and Validation of a Risk Assessment Model for Immunomodulatory Drug–Associated Thrombosis Among Patients With Multiple Myeloma
- (2019) Ang Li et al. Journal of the National Comprehensive Cancer Network
- A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma
- (2018) Elizabeth K. O'Donnell et al. BRITISH JOURNAL OF HAEMATOLOGY
- Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma
- (2018) Paul G. Richardson et al. BRITISH JOURNAL OF HAEMATOLOGY
- A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma
- (2018) Shira Dinner et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Phase II Clinical Trial of Lenalidomide and Dexamethasone Therapy in Japanese Elderly Patients With Newly Diagnosed Multiple Myeloma to Determine Optimal Plasma Concentration of Lenalidomide
- (2018) Takahiro Kobayashi et al. THERAPEUTIC DRUG MONITORING
- Global Burden of Multiple Myeloma
- (2018) Andrew J. Cowan et al. JAMA Oncology
- Association of venous thromboembolism with increased mortality in patients with multiple myeloma.
- (2018) Martin W. Schoen et al. JOURNAL OF CLINICAL ONCOLOGY
- Venous thromboembolism in multiple myeloma - choice of prophylaxis, role of direct oral anticoagulants and special considerations
- (2018) Dawn Swan et al. BRITISH JOURNAL OF HAEMATOLOGY
- Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
- (2018) Graham H Jackson et al. LANCET ONCOLOGY
- Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial
- (2018) Elisabet E Manasanch et al. Lancet Haematology
- Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077)
- (2017) Juliane Beck et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study
- (2017) Jian Hou et al. Journal of Hematology & Oncology
- Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial
- (2017) Brian G M Durie et al. LANCET
- Lenalidomide, adriamycin, dexamethasone for induction followed by stem-cell transplant in newly diagnosed myeloma
- (2017) S Knop et al. LEUKEMIA
- Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial
- (2017) Sarah A Holstein et al. Lancet Haematology
- Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies
- (2017) Weijuan Li et al. JAMA Oncology
- Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma
- (2016) Sonja Zweegman et al. BLOOD
- Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma
- (2016) I. S. Nijhof et al. BLOOD
- Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma
- (2016) Valeria Magarotto et al. BLOOD
- Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd-line therapy for relapsed and refractory multiple myeloma - a phase II trial
- (2016) Ulrich J. M. Mey et al. BRITISH JOURNAL OF HAEMATOLOGY
- Lenalidomide and low-dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: A phase II study
- (2016) Kenshi Suzuki et al. CANCER SCIENCE
- Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial
- (2016) Andrew J Yee et al. LANCET ONCOLOGY
- Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Philippe Moreau et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Thromboprophylaxis in multiple myeloma patients treated with lenalidomide – A systematic review
- (2016) Fatimah Al-Ani et al. THROMBOSIS RESEARCH
- Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma
- (2015) Shaji K Kumar et al. AMERICAN JOURNAL OF HEMATOLOGY
- Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma
- (2015) A. K. Stewart et al. BLOOD
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
- (2015) Sagar Lonial et al. NEW ENGLAND JOURNAL OF MEDICINE
- Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
- (2015) A. Keith Stewart et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantation
- (2015) V Roy et al. Blood Cancer Journal
- Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma
- (2015) Neha Korde et al. JAMA Oncology
- A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma
- (2014) P. G. Richardson et al. BLOOD
- Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma
- (2014) Donna E. Reece et al. BRITISH JOURNAL OF HAEMATOLOGY
- Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide
- (2014) Andrew J. Yee et al. BRITISH JOURNAL OF HAEMATOLOGY
- Front-Line Transplantation Program With Lenalidomide, Bortezomib, and Dexamethasone Combination As Induction and Consolidation Followed by Lenalidomide Maintenance in Patients With Multiple Myeloma: A Phase II Study by the Intergroupe Francophone du Myélome
- (2014) Murielle Roussel et al. JOURNAL OF CLINICAL ONCOLOGY
- International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation
- (2014) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study
- (2014) Shaji K Kumar et al. LANCET ONCOLOGY
- Expression of B-cell-associated genes in peripheral blood mononuclear cells of patients with symptomatic pulmonary embolism
- (2014) WEI LV et al. Molecular Medicine Reports
- Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
- (2014) Lotfi Benboubker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens
- (2013) Tina Bagratuni et al. AMERICAN JOURNAL OF HEMATOLOGY
- Mature results of MM-011: A phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma
- (2013) Aleksandr Lazaryan et al. AMERICAN JOURNAL OF HEMATOLOGY
- Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma
- (2013) Rachid C. Baz et al. AMERICAN JOURNAL OF HEMATOLOGY
- Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma
- (2013) M. Wang et al. BLOOD
- Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077
- (2013) Wolfram Pönisch et al. BRITISH JOURNAL OF HAEMATOLOGY
- Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma
- (2013) R. Niesvizky et al. CLINICAL CANCER RESEARCH
- A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial
- (2013) Jian Hou et al. Journal of Hematology & Oncology
- MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs
- (2013) Philippe Rodon et al. THROMBOSIS AND HAEMOSTASIS
- Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma
- (2012) S. Kumar et al. BLOOD
- Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study
- (2012) S. Lentzsch et al. BLOOD
- A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
- (2012) A. J. Jakubowiak et al. BLOOD
- Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
- (2012) Sagar Lonial et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma
- (2012) J R Berenson et al. LEUKEMIA
- Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma
- (2012) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Philip L. McCarthy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: Results from a phase 2 trial
- (2011) Shaji K. Kumar et al. AMERICAN JOURNAL OF HEMATOLOGY
- Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial
- (2011) A. J. Jakubowiak et al. BLOOD
- Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide
- (2011) A. Larocca et al. BLOOD
- Low Venous Thromboembolic Risk With Bortezomib in Multiple Myeloma and Potential Protective Effect With Thalidomide/Lenalidomide-based Therapy: Review of Data From Phase 3 Trials and Studies of Novel Combination Regimens
- (2011) Maurizio Zangari et al. Clinical Lymphoma Myeloma & Leukemia
- Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial
- (2011) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis
- (2011) M. CARRIER et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Thrombosis in Multiple Myeloma
- (2011) S. Y. Kristinsson Hematology-American Society of Hematology Education Program
- Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study
- (2010) S. Y. Kristinsson et al. BLOOD
- Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
- (2010) P. G. Richardson et al. BLOOD
- Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
- (2010) Michele Cavo et al. LANCET
- Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom)
- (2009) S. Knop et al. BLOOD
- Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
- (2009) S Vincent Rajkumar et al. LANCET ONCOLOGY
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. PLOS MEDICINE
- Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma
- (2008) S. Y. Kristinsson et al. BLOOD
- Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping
- (2008) D. C. Johnson et al. BLOOD
- Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma
- (2008) Sagar Lonial et al. BRITISH JOURNAL OF HAEMATOLOGY
- Thromboembolic events with lenalidomide-based therapy for multiple myeloma
- (2008) Smitha Patiyil Menon et al. CANCER
- Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma
- (2008) M. Zangari et al. HAEMATOLOGICA
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
- (2008) Jesús F. San Miguel et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started